Provided by Tiger Trade Technology Pte. Ltd.

Natera

332.03
+7.192.21%
Post-market: 333.301.27+0.38%19:59 EDT
Volume:1.22M
Turnover:399.64M
Market Cap:47.55B
PE:-241.85
High:332.98
Open:325.00
Low:320.41
Close:324.84
52wk High:333.56
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:0.84
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:26.11
PE(LYR):-217.46

Loading ...

Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 03

When Multi-cancer Blood Screens Could Finally Take Off

Dow Jones
·
Jul 02

Movement Alert|Natera Falls 5.1% in After-Hours Trading, Trading at $270.25

Market Focus
·
Jul 01

Natera is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Natera, Aveta Biomics announce strategic partnership

TIPRANKS
·
Jun 29

Natera Partners with Aveta Biomics on Phase 3 Apg-157 Head and Neck Cancer Trial

Reuters
·
Jun 29

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29

Natera - Phase 3 Trial Expected to Begin Enrollment in Second Half of 2026

THOMSON REUTERS
·
Jun 29

Natera Director Herm Rosenman Disposes of 16,530 Shares for $4.13 Million

Reuters
·
Jun 27

Natera Price Target Announced at $310.00/share by Bernstein

Dow Jones
·
Jun 26

Natera Inc : Bernstein Resumes Coverage with Outperform Rating; Price Target $310

THOMSON REUTERS
·
Jun 26

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25

Movement Alert|Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan

Market Focus
·
Jun 25

Street View: Japan Nod for Natera's Cancer Test Meaningful, but Payoff Seen Later

Reuters
·
Jun 24

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

MT Newswires Live
·
Jun 24

Natera : Barclays Cuts Target Price to $260 from $280

THOMSON REUTERS
·
Jun 24

Natera announces Signatera receives regulatory approval in Japan

TIPRANKS
·
Jun 24

BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer

Reuters
·
Jun 24